Saturday 17 October 2026
Export ZYBT’s income statement to Excel — free account
Zhengye Biotechnology Holding Limited
ZYBT Healthcare Drug Manufacturers Specialty & Generic
Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
1.43
0.07
−4.67%
Follow ZYBT
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Piotroski F-Score |
— | — | 2 |
Altman Z-Score |
— | — | 1.47 |
Altman Z″-Score (non-manufacturers) |
3.80 | 3.73 | 1.49 |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
P/Operating CF |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | (2.26) | (3.71) |
P/B ratio |
0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 0.43 |
EV/FCF |
0.00 | 0.00 | 0.61 |
Quick Ratio |
0.72 | 0.69 | 0.60 |
Current Ratio |
1.37 | 1.31 | 1.14 |
Net Debt/EBITDA |
0.89 | 1.64 | (0.51) |
Debt/Assets |
17.97% | 17.52% | 17.10% |
Debt/Equity |
0.26 | 0.25 | 0.24 |
Asset Turnover |
0.00 | 0.37 | 0.26 |
Operating CF/Net income |
1.53 | 3.63 | (0.19) |
Capex/Depreciation |
(0.44) | (1.14) | (0.49) |
Interest Coverage |
10.16 | 4.07 | (20.75) |
| 0.00% | 3.26% | (21.66%) | |
| 0.00% | 2.27% | (15.36%) | |
ROIC |
7.02% | 2.45% | (13.38%) |
Return on Tangible Assets |
9.87% | 3.81% | (27.51%) |
Average Days of Receivables |
136.69 | 144.38 | 64.91 |
Research and Development Expense of Revenue |
5.62% | 6.87% | 15.48% |
Selling, General and Administrative Expense of Revenue |
31.48% | 34.26% | 64.39% |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.13 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% |
Revenue per Share |
0.64 | 0.56 | 0.35 |
Operating CF per Share |
0.15 | 0.12 | 0.04 |
Capex per Share |
(0.03) | (0.08) | (0.04) |
Free Cash Flow per Share |
0.11 | 0.04 | 0.00 |
Cash per Share |
0.09 | 0.06 | 0.16 |
Shareholders Equity per Share |
1.02 | 1.06 | 0.93 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
1.02 | 1.06 | 0.93 |
Free Cash Flow |
5.18 | 1.83 | 0.11 |
Working Capital |
7.62 | 5.71 | 2.42 |
Capital Expenditures |
(1.45) | (3.79) | (1.81) |
Net Current Asset Value |
6.19 | 5.05 | 1.09 |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.05 | 0.15 | 0.11 |
| Other line items | |||
Depreciation/Fixed assets |
0.09 | 0.09 | 0.11 |
Cash ROIC |
8.23% | 2.92% | 0.17% |
Accounts Receivable Turnover |
0.00 | 2.43 | 2.55 |
Accounts Payable Turnover |
0.00 | 2.14 | 2.17 |
Inventory Turnover |
0.00 | 1.63 | 1.95 |
Average Days of Payables |
203.71 | 164.94 | 173.74 |
Days of Inventory on Hand |
260.13 | 223.57 | 154.56 |
Average Receivables |
— | 10.50 | 6.53 |
Average Payables |
— | 6.08 | 6.09 |
Average Inventory |
— | 8.00 | 6.79 |
Average Assets |
— | 68.18 | 64.99 |
Average Common Equity |
— | 47.49 | 46.08 |
Columns are period end dates